Keyword: Flublok

Sanofi will increase the supplies of Flublok Quadrivalent and Fluzone High-Dose to 25 million doses for the coming flu season.

Seqirus' cell-based flu vaccine was 26.5% effective at keeping those 65 and older out of the hospital in the past flu season, an FDA study finds.

Sanofi raised the price of Flublok by 12.5% last year, its only increase above the U.S. National Health Expenditure growth rate.

Sanofi's net prices fell 8.4% last year, the drugmaker reported in an update to its pricing policies.

The licensing deal provides Sanofi Pasteur access to a cell culture technology for use in its universal influenza vaccine.

Not long after its acquisition by Sanofi, Protein Sciences is bidding adieu to its former leader.

Health experts presented flu vaccination guidelines stressing there's no difference in safety for shots given people allergic to eggs.

Though not nearly on the scale of Sanofi's runs at Medivation or Actelion, the Protein Sciences buyout promises a boost for its flu vaccines lineup.

Astellas pulled the plug on a cell culture flu vaccine partnership with UMN Pharma after Japanese regulators stiff-armed its application for approval.